---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-052109"
form_type: "8-K"
ticker: "KURA"
cik: "0001422143"
company_name: "Kura Oncology, Inc."
filed_at: "2024-05-02T23:59:59+00:00"
generated_at: "2026-06-03T00:15:47.896453+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Kura Oncology Q1 net loss $49.5M, cash $527M; ziftomenib gets BTD for NPM1-mutant AML

## Summary
- Net loss of $49.5M in Q1 2024 vs $34.1M in Q1 2023; cash $527M provides runway into 2027.
- FDA granted Breakthrough Therapy Designation to ziftomenib for relapsed/refractory NPM1-mutant AML based on KOMET-001 data.
- Registration-directed trial of ziftomenib in NPM1-mutant AML on track to complete enrollment of 85 patients by mid-2024.
- Positive preliminary combo data: 100% CR rate in newly diagnosed with ziftomenib + 7+3; 53% ORR in R/R with venetoclax/azacitidine.
- First patient dosed with KO-2806 + cabozantinib in RCC; on track to dose with adagrasib in KRASG12C NSCLC by mid-2024.

## SEC filing metadata
- accession: 0000950170-24-052109
- form_type: 8-K
- ticker: KURA
- cik: 0001422143
- company_name: Kura Oncology, Inc.
- filed_at: 2024-05-02T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1422143/000095017024052109/0000950170-24-052109-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1422143/000095017024052109/kura-20240502.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-052109
- JSON: https://secwatch.observer/filing/0000950170-24-052109.json
- Plain text: https://secwatch.observer/filing/0000950170-24-052109.txt

## Key facts
- Earnings Releases
  Kura Oncology, Inc. reported the first quarter ended March 31, 2024 results: net income Net loss for the first quarter of 2024 was $49.5 million.
  - Period: the first quarter ended March 31, 2024
  - Net income: Net loss for the first quarter of 2024 was $49.5 million
  - Result: reported results
  source text: Kura Oncology, Inc. (the "Company") issued a press release announcing the Company's financial results for the first quarter ended March 31, 2024 and providing a corporate update.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1422143/000095017024052109/0000950170-24-052109-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.